https://ipharmag.com/article/what-is-a-jak-inhibitor-explained-uses-side-effects iPharmag en 2026-10-01T12:41:35+00:00 What Is a JAK Inhibitor? How They Work, What They Treat, and the Risks to Know https://ipharmag.com/article/sanofi-regeneron-8b-long-acting-dupixent-successors iPharmag en 2026-10-01T12:41:35+00:00 Sanofi and Regeneron Strike an $8 Billion Deal to Build Dupixent’s Successors https://ipharmag.com/article/fda-approves-camzyos-adolescents-obstructive-hcm iPharmag en 2026-10-01T12:41:35+00:00 FDA Expands Camzyos to Teenagers With Obstructive Hypertrophic Cardiomyopathy https://ipharmag.com/article/novo-nordisk-hengrui-oral-weekly-obesity-pill-deal iPharmag en 2026-09-30T03:50:00+00:00 Novo Nordisk Pays $300M Upfront for a Once-Weekly Obesity Pill From China’s Hengrui https://ipharmag.com/article/leqembi-vs-kisunla-alzheimers-drugs-compared iPharmag en 2026-09-30T03:50:00+00:00 Leqembi vs. Kisunla: How the Two Alzheimer’s Antibody Drugs Compare https://ipharmag.com/article/astrazeneca-summit-2b-ivonescimab-gi-cancer-collaboration iPharmag en 2026-09-30T03:50:00+00:00 AstraZeneca Invests $2 Billion in Summit to Pair Ivonescimab With Its Cancer ADCs